3 ms·
So don't let people sell the drugs at a profit, at early stages.
by DennisP 9mo ago
So don't let people sell the drugs at a profit, at early stages.
- Induane 9mo agoDing ding ding this is the way. Sell at cost. Real cost, like cost of making. NOT a cost that includes R&S amortized across the batch.
- vibrio 9mo agoNot even cost plus? Not sure how that works, from the viewpoint of economic incentives.
- ulfw 9mo agoIt's literally free data for efficacy / later sales.
- vibrio 9mo agoSo charging patients/insurance companies at cost to fund the clinical studies?
- DennisP 9mo agoClinical studies today are funded entirely by the pharma companies, keep that. Selling at cost of production would be something extra, for patients who want the drugs but aren't enrolled in an actual study. The company doesn't get solid data it can use for regulatory approval, so making them donate the drugs in that case seems excessive. A downside would be that for drugs that don't cost much to produce, patients might be less willing to enroll in the studies, given the chance of getting a placebo. That could be handled by shutting down the informal access while the study is enrolled, for anyone who's eligible. I'm sure there are other wrinkles that would need to be considered too.
- vibrio 9mo agoPut this way, this seems reasonable. Beyond cell therapy, I don't thin the cost of drug is the motivation for not making it more freely available. 'Misuse' leading to potential liability or unjustified bad outcomes, along with some regulatory burden seems like the issue.
- kulahan 9mo agoOh sick, so every time my company faces an economic downturn, I can shift huge amounts of workers to a program designed to sell unfinished drugs at cost! Like, it doesn’t even have to be viable, just start selling saline with coloring or something. Unless it does have to be somewhat viable, which is… regulation.
- DennisP 9mo agoI'm not against regulation in principle. In this case, full disclosure of exactly what's in the drug should definitely be required. People's doctors can make informed decisions after that. Restricting this to patients who are otherwise out of options is probably also a good idea. Pancreatic cancer would certainly qualify.